Endometriosis

165

Pipeline Programs↗

35

Active Trials↗

56

Companies Involved↗

Endometriosis is a highly competitive landscape with 165 programs across 56 companies. The most active players are Bristol-Myers Squibb, Prism Pharmaceuticals, Repros Therapeutics Inc.. 30 therapies are approved with 37 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

36/100

Mech. Concentration

9/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Bristol-Myers Squibb

1 program

Prism Pharmaceuticals

1 program

Repros Therapeutics Inc.

2 programs

Mereo BioPharma

2 programs

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Gesynta Pharma AB

1 program

Analysis

Modality Breakdown

96%

Small molecule

186 of 193 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 193 classified programs, each share of the total. Modality classified for 100% of 200 pipeline programs.

Analysis

Trial Status

217

clinical trials

Completed122 · 56%

Unknown status32 · 15%

Recruiting25 · 12%

Terminated18 · 8%

Withdrawn10 · 5%

Not yet recruiting5 · 2%

Other5 · 2%

Clinical Trials

Trial Activity

217 trials

Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

Recruiting·AAlcea·Phase 3·NCT07164183·290 enrolled

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

Recruiting·UUniversity of Michigan·Phase 3·NCT07100782·130 enrolled

Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis

Recruiting·BBio Meds Pharmaceutica Ltda·Phase 4·NCT06543550·70 enrolled

Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI

Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT05480995·24 enrolled

Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine

Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT06951802·118 enrolled

Glycemic Regulation as Endometriosis Adjunct Treatment

Recruiting·—·Phase 2·NCT06611501·14 enrolled

Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis

Recruiting·—·Phase 4·NCT06577233·60 enrolled

Endometriosis and Microvascular Dysfunction: Role of Inflammation

Recruiting·PPenn State University·Phase 1·NCT05069740·24 enrolled

Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

Recruiting·UUniversity of Udine·N/A·NCT06414720·90 enrolled

Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study

Recruiting·RReinier de Graaf Groep·Phase 3·NCT06161805·56 enrolled

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Recruiting·MMain Line Health·Phase 3·NCT06439524·110 enrolled

Role of Medical Treatment in Endometriosis Patients Undergoing ICSI

Recruiting·—·N/A·NCT06577974·129 enrolled

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Recruiting·HHopital Foch·Phase 2/3·NCT04356664·180 enrolled

Clinical and Molecular Study of Endometriosis and Adenomyosis

Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04481321·5,300 enrolled

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

Recruiting·YYale University·Phase 3·NCT06375811·297 enrolled

Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)